STOCK TITAN

Evolus to Participate in Stifel 2024 Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
conferences

Evolus (NASDAQ: EOLS), a performance beauty company focused on aesthetics, has announced its upcoming participation in the Stifel Healthcare Conference. The company's management team will deliver a presentation in New York City on Tuesday, November 19 at 10:55 AM ET.

Interested parties can access the presentation through the Investor Relations section of the Evolus website. The webcast will remain available for replay for 90 days following the presentation date.

Evolus (NASDAQ: EOLS), un'azienda specializzata in bellezza e performance, ha annunciato la sua prossima partecipazione alla Stifel Healthcare Conference. Il team di gestione dell'azienda presenterà a New York City martedì 19 novembre alle 10:55 AM ET.

Le parti interessate possono accedere alla presentazione attraverso la sezione Relazioni con gli Investitori del sito web di Evolus. La trasmissione in streaming rimarrà disponibile per la visione per 90 giorni dopo la data della presentazione.

Evolus (NASDAQ: EOLS), una empresa de belleza enfocada en el rendimiento, ha anunciado su próxima participación en la Stifel Healthcare Conference. El equipo de gestión de la compañía realizará una presentación en la ciudad de Nueva York el martes 19 de noviembre a las 10:55 AM ET.

Las partes interesadas pueden acceder a la presentación a través de la sección de Relaciones con Inversionistas en el sito web de Evolus. La transmisión permanecerá disponible para su repetición durante 90 días después de la fecha de la presentación.

Evolus (NASDAQ: EOLS), 미용 성과에 중점을 둔 회사가 Stifel Healthcare Conference에 참석할 것이라고 발표했습니다. 회사의 경영팀은 뉴욕시에서 11월 19일 화요일 오전 10:55(Eastern Time)에 발표할 예정입니다.

관심 있는 분들은 Evolus 웹사이트의 투자자 관계 섹션을 통해 발표에 접근할 수 있습니다. 웹캐스트는 발표일로부터 90일 동안 재생할 수 있습니다.

Evolus (NASDAQ: EOLS), une entreprise spécialisée dans la beauté et la performance, a annoncé sa prochaine participation à la Stifel Healthcare Conference. L’équipe de direction de l’entreprise fera une présentation à New York le mardi 19 novembre à 10h55 ET.

Les parties intéressées peuvent accéder à la présentation via la section Relations Investisseurs du site web d’Evolus. Le webcast restera disponible en replay pendant 90 jours après la date de la présentation.

Evolus (NASDAQ: EOLS), ein Unternehmen, das sich auf Schönheitsleistungen spezialisiert hat, hat seine bevorstehende Teilnahme an der Stifel Healthcare Conference bekannt gegeben. Das Managementteam des Unternehmens wird am Dienstag, den 19. November um 10:55 Uhr ET eine Präsentation in New York City halten.

Interessierte Parteien können die Präsentation über den Bereich Investor Relations auf der Evolus-Website abrufen. Der Webcast wird 90 Tage nach dem Präsentationsdatum für eine Wiederholung zur Verfügung stehen.

Positive
  • None.
Negative
  • None.

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the Stifel Healthcare Conference in New York City on Tuesday, November 19 at 10:55 AM ET.

The presentation can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available for 90 days after the date of the presentation.

About Evolus, Inc.

Evolus (NASDAQ: EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, and the exclusive distributor in Europe of Estyme®, a line of unique injectable hyaluronic acid (HA) gels. These injectable HA gels are currently in the late stages of the regulatory approval process, with plans, upon approval, for a launch starting in 2025. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.

Jeuveau® and Nuceiva®, are registered trademarks and Evolysse™ is a trademark of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
Estyme® is a trademark of Symatese Aesthetics S.A.S.

Investors:

Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications

Phone: (248) 202-9267

Email: ir@evolus.com

Media:

Email: media@evolus.com

Source: Evolus

FAQ

When is Evolus (EOLS) presenting at the Stifel 2024 Healthcare Conference?

Evolus will present at the Stifel Healthcare Conference on Tuesday, November 19 at 10:55 AM ET in New York City.

How long will the Evolus (EOLS) Stifel Conference presentation replay be available?

The webcast replay will be available for 90 days after the presentation date.

Where can I watch Evolus (EOLS) Stifel Conference presentation?

The presentation can be accessed through the Investor Relations page of the Evolus website.

What type of company is Evolus (EOLS)?

Evolus is a performance beauty company focused on building an aesthetic portfolio.

Evolus, Inc.

NASDAQ:EOLS

EOLS Rankings

EOLS Latest News

EOLS Stock Data

816.85M
50.17M
12.31%
80.2%
8.59%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
NEWPORT BEACH